24 March 2026

Clean Power Hydrogen plc

("CPH2" or the "Company")

Memorandum of Understanding with Siemens plc

CPH2 (AIM:CPH2), which has developed market disrupting and IP-protected Membrane-Free Electrolyser ("MFE") technology for the production of commercial high purity hydrogen and above medical-grade purity oxygen, announces that it has entered into a non-binding Memorandum of Understanding ("MOU") with Siemens plc. It is the intention of Siemens and CPH2 to conclude a legally binding agreement in relation to Siemens assisting CPH2 across a range of activities focussed on successfully scaling up CPH2's MFE production and maintaining its technology leadership.

Further updates in respect of the progress towards a legally binding agreement between the parties will follow in due course.

Commenting, Chief Executive Officer of CPH2, Jon Duffy, said: "Our discussions with Siemens cover a range of activities from enhanced process and automation to customer introduction, marketing, 24/7 technical support, training, joint product and process development and Go-to-Market strategies, all with the objective to upscale CPH2 production. We look forward to updating the Market further on this in due course."

ENDS

Enquiries:

Background on CPH2

CPH2 is the holding company of Clean Power Hydrogen Group Limited which has a decade of dedicated research and product development experience that has delivered global patents in breakthrough hydrogen and oxygen production technology. The Group's strategic objective is to deliver the lowest lifetime Levelised Cost of Hydrogen ("LCOH") in the market in relation to the production of hydrogen at this scale. CPH2 is listed on the AIM market and trades under the ticker LSE: CPH2.

For more information: https://www.cph2.com